The volatile anaesthetic agents are known to influence uterine muscle tone. All of the agents studied to date have been found to produce uterine relaxation. This property has been used to produce therapeutic uterine relaxation for difficult obstetric deliveries and the Ex Utero Intrapartum Treatment (EXIT) procedure. This study describes the effects of sevoflurane on isolated human myometrium at concentrations of 0.1, 0.25, 0.5, 0.75, 1.0, 1.5, 2.5 and 3.5 MAC. Sevoflurane produces dose-dependent depression of uterine muscle contractility with an ED 50 of 0.94 MAC. Frequency of contraction was increased at concentrations of 2.5 MAC and greater. At concentrations of 3.5 MAC and above, uterine activity was virtually abolished.
The control of uterine muscle tone is an important consideration for the obstetric anaesthetist. Therapeutic uterine relaxation may be required for manual removal of retained placenta 1 , complicated breech extraction and twin delivery 2 , treatment of uterine inversion 3 and intrapartum cephalic version of the second twin 4 . Recently, the EXIT procedure has been described, whereby neonates with obstructive airway masses are delivered during caesarean section. Fetal gas exchange is maintained by the uteroplacental circulation 5 . This procedure allows time for an airway to be established prior to separation of the neonate from the mother. During this procedure uterine relaxation is critical, not only for surgical access but also because concurrent uterine contraction may impair placental perfusion and cause fetal hypoxaemia.
Deep isoflurane anaesthesia has been used to maintain uterine quiescence during the EXIT procedure 6 . Isoflurane has been chosen because the effect of this drug on the uterus has been investigated and it is known to produce a dose-related depression of uterine contractility 7 . Recently, sevoflurane has been used at our institution to produce uterine relaxation during the EXIT procedure. This agent has several potential advantages over isoflurane. The lower blood-gas partition coefficient of sevoflurane confers the property of more rapid washin and washout of the drug 8 . This may be particularly beneficial following the delivery of the fetus, where prolonged uterine relaxation may result in increased perioperative blood loss. Furthermore, sevoflurane produces less cardiovascular depression than isoflurane 9 and this may in itself be of benefit to both mother and fetus. To date, there are no reports in the literature of the effects of sevoflurane on gravid human myometrium.
The purpose of this study was to describe the effects of sevoflurane on the isolated gravid human myometrium over a wide range of concentrations. The results may assist the obstetric anaesthetist in choosing appropriate concentrations of sevoflurane for the purposes of uterine relaxation. The description of the effects of high concentrations of sevoflurane is particularly relevant to operations such as the EXIT procedure, where profound uterine relaxation is critical to neonatal wellbeing.
MATERIALS AND METHODS
The regional Ethics Committee approved this study. Following written informed consent, a small sample of myometrium was taken from the upper edge of the lower segment incision from healthy term parturients during elective caesarean section under epidural or spinal anaesthesia. Indications for caesarean section included breech presentation, cephalopelvic disproportion, twin pregnancy, and prior caesarean section. In total, 12 specimens were obtained and immediately stored at 5°C in Kreb's solution (Na + 145, K + 6, Ca 2+ 2.5, Mg 2+ 1.2, HCO 3 -25 and glucose 11 mmol/l). Specimens were used within three hours of harvest. Using a dissecting microscope, small myometrial strips (1 mmx2 mmx10 mm) were prepared from the harvested tissue and suspended in an organ bath containing the Kreb's solution bubbled with 5% carbon dioxide (CO 2 ) and 95% oxygen (O 2 ) (carbogen) at 37°C. Bath pH was maintained between 7.40 and 7.48. All specimens had a baseline tension applied and maintained between 2 and 2.5 g. Force of contraction was measured with an FT03 isometric force transducer (Grass Instruments) and recorded using Powerlab hardware and Chart for Windows software (AD Instruments). Following warming in the organ bath, all specimens developed spontaneous contractions within 90 minutes. Contractility was defined as the area under the force-time curve. Developed tension was defined as the difference between the baseline and the maximum height of the contraction. Three consecutive contractions were measured prior to exposure to sevoflurane and the mean values of these three contractions were used as the control. Sevoflurane was then introduced into the carbogen gas using a Datum vaporizer (Abbott) and bubbled through the organ bath. The concentration of sevoflurane was measured continuously using a sidestream infrared gas analyser (Capnomac Ultima, Datex), calibrated with calibration gas (Quick Cal, Datex Engstrom) at the point that the gas was introduced into the organ bath. Following a 10 minute equilibration period with sevoflurane, the mean values for three consecutive contractions were measured and expressed as a percentage of the preceding control measurements. Administration of volatile agent was then discontinued, the organ bath was flushed with fresh pre-warmed Kreb's solution, and a 10 minute equilibration time was allowed. This sequence, including control measurements prior to exposure, was repeated for each concentration of sevoflurane investigated. In this way, the effects of the differing concentration of sevoflurane could be compared with control measurements immediately prior to exposure. This methodology was chosen to minimize the potential effects of deterioration of the specimen over time. The concentration of sevoflurane investigated corresponded to 0.1, 0.25, 0.5, 0.75, 1.0, 1.5, 2.5 and 3.5 MAC. The 1 MAC value used for sevoflurane was 2.01% 10 . As a result of specimen deterioration, determined by a greater than 25% depression of control measurement over time, it was not possible to test all concentrations on a single specimen. Six specimens (group 1) were exposed to concentrations corresponding to 0.1, 0.25, 0.75, 2.5 and 3.5 MAC and six specimens (group 2) were exposed to concentrations corresponding to 0.5, 1.0 and 1.5 MAC. The order of exposure in both groups was varied sequentially, once again to minimize any potential effects of specimen deterioration over time.
Initial control measurements of the two sets of data were compared and tested with the Student's t-test. The experimental data were analysed using ANOVA with Newman-Keuls multiple comparisons. Statistical analyses were performed using a personal computer based package (Number Cruncher Statistical System, JL Hintze, Kaysville, Utah, U.S.A.). Results were considered to be statistically significant when P<0.05. The text and table data are presented as mean±standard error.
RESULTS
A typical recording of the spontaneous contractions during the control measurements and after exposure to 3.5 MAC has been reproduced in Figure  1 . The initial control contractions in both groups with respect to frequency, mean developed tension and area under the curve were not significantly different. Subsequent control contractions were within 15% of the initial values in the same group, except for the frequency control value preceding exposure to 2.5 MAC sevoflurane (23% less than control) and the contractility control value prior to exposure to 1.0 MAC (23% greater than control). These differences were not statistically different (Table 1) .
Sevoflurane depressed uterine contractility, defined as the area under the force-time curve, in a dose-dependent fashion ( Figure 2 ). The doseresponse curve is sigmoid in shape with a 50% effective dose (ED50) of 0.94 MAC. The depression of uterine contractility observed with sevoflurane was statistically significant at concentrations of 0.5 MAC and greater. Minimal activity was observed at concentrations of greater than 2.5 MAC. At 3.5 MAC uterine muscle activity was abolished in all but one of the specimens.
Developed tension (grams), which we have defined as the difference in tension between the baseline measurement and the peak tension during a contraction, was similarly depressed in a dose-dependent fashion ( Figure 3 ). This depression was significant for sevoflurane concentrations of 1 MAC and greater.
Frequency of contraction was also influenced by sevoflurane. In determining the frequency of contraction, specimens that demonstrated complete depression of contractile activity were excluded from the analysis. Contractions were abolished in one specimen at 1.5 MAC, two specimens at 2.5 MAC and five specimens at 3.5 MAC. At lower concentrations of sevoflurane (0.1-1.5 MAC), there was a nonsignificant trend towards an increased frequency of contractions with increasing concentration. At 2.5 and 3.5 MAC, sevoflurane significantly increased the frequency of contraction (Figure 4) .
DISCUSSION
This is the first report of the effects of sevoflurane on gravid human uterine muscle and the first time that the effects of a volatile anaesthetic agent on gravid human uterine muscle tone have been described over a wide range of concentrations. We found that sevoflurane produces dose-dependent depression of contractility and developed tension of isolated gravid human myometrium. These findings are consistent with previous studies investigating the effects of the volatile anaesthetic agents on uterine muscle tone.
There are several limitations to this study. In vitro results cannot be directly extrapolated to the clinical setting. Whilst it might be considered logical to conclude that a similar degree of depression of uterine contractility observed in the laboratory occurs in the intact organism, this remains unknown. On the other hand, this in vitro study allows control of the many variables that cannot be controlled in the clinical setting. Thus, the majority of work on this area to date has been conducted using isolated muscle. In this study, we combined the results of two separate experimental runs to produce a complete doseresponse curve. This methodological approach is not ideal, however the limitations of the preparation did not allow us to test all of the concentrations that we have presented in this study on one single muscle strip. The muscle strips were not sufficiently robust to maintain consistent contraction throughout the period of time required for testing all the specified concentrations. Nevertheless, we do not believe that this approach has biased our results. There was no significant difference between the initial control measurements in both groups. The degree of depression of contractility was consistent with increasing concentrations of sevoflurane and the specimens did not show any significant degree of deterioration, defined by a 25% or greater reduction in control measurements over the time of the experiment.
The volatile anaesthetic agents have been used to produce uterine relaxation for intraoperative therapeutic uterine relaxation [11] [12] [13] [14] [15] . Advantages of these agents include rapidity of onset and offset, especially at the lower range of concentrations, convenience and the avoidance of polypharmacy with the possibility of associated unwanted drug interactions. Furthermore, agents such as glyceryl trinitrate, which may also be used to relax the uterus, may be less effective when used in combination with the general anaesthetic agents, although the mechanism of this interaction is not well understood 16 . There are disadvantages to using the volatile anaesthetic agents for uterine relaxation. High concentrations are often required for uterine relaxation and washout is not as rapid. Uterine relaxation achieved with these high concentrations may be slower to resolve and this may lead to increased blood loss. The volatile anaesthetic agents produce maternal cardiovascular depression which, if uncorrected, may result in compromised placental perfusion. The volatile anaesthetic agents cross the placenta, resulting in central nervous system depression of the neonate following delivery 17 . The use of these agents for obstetric anaesthesia has also been associated with increased perioperative blood loss. Blood loss during obstetric procedures may be increased two-to four-fold when general anaesthesia is used in preference to a regional technique and the use of a volatile agent has been shown to be an independent risk factor for increased blood loss [18] [19] [20] .
Despite these disadvantages, the volatile anaesthetic agents are useful for therapeutic uterine relaxation. Recently, the EXIT procedure has provided a compelling new indication for profound uterine relaxation. During this operation, the neonate is partially delivered and maintained by the uteroplacental circulation. This technique is used to allow the surgical and anaesthetic teams time to establish an airway in the presence of an obstructive airway lesion, diagnosed prior to delivery. During this procedure, uterine activity may have devastating consequences, including placental separation and neonatal hypoxaemia 21 . Uterine relaxation during the EXIT procedure has generally been achieved with deep isoflurane anaesthesia because its effect on uterine tone has been well-described 5, 6, 22, 23 . However, it is interesting that the highest isoflurane concentration investigated in vitro for its effect on uterine muscle tone is 1.5 MAC, well below the concentrations routinely used during the EXIT procedure.
The effect of halothane, enflurane and isoflurane on isolated gravid human myometrium has been studied. Direct comparisons with our work are confounded by the differing methodologies used by other investigators. However, all such studies demonstrate that the volatile anaesthetic agents depress uterine muscle tone, with the degree of depression quite variable. At concentrations of 1.0 MAC for example, halothane depressed uterine activity by 63%-87% when activity was expressed in terms of percent of control values. The ED 50 of halothane varies from 1.7 to 2.4 MAC 7,24-27 . Isoflurane was found to depress the activity of the uterus to 83% of control at 0.5 MAC, 73% of control at 1.0 MAC and 41% of control at 1.5 MAC 7 . Higher concentrations were not studied. A limitation of this particular study is that gravid and non-gravid samples were investigated together and it is well recognized that these tissues behave quite differently when exposed to the volatile anaesthetic agents. Several studies have described the effects of halothane and enflurane on non-gravid human myometrium. While these studies confirm that these agents depress non-gravid uterine activity, the results cannot be applied to the pregnant uterus 25, 26 . The effect of sevoflurane on isolated gravid rat uterine muscle has been studied 28 . In this study, sevoflurane did not produce the same degree of depression that we observed in human tissue. Our study also demonstrated that sevoflurane caused an increased frequency of uterine muscle contraction at higher concentrations, but the individual contractions were reduced markedly in both amplitude and duration. Other investigators have not reported an increase in frequency with increasing concentration of volatile anaesthetic agents. Halothane, enflurane and isoflurane appear to decrease the frequency of uterine contraction of isolated human myometrium, at least up to concentrations of 1.5 MAC 7, 24, 29 .
Sevoflurane has several potential advantages over other volatile anaesthetic agents. It does not sensitize the myocardium to catecholamines and has not been reported to produce hepatic damage or renal toxicity in the clinical setting 30 . Furthermore, sevoflurane has a relatively rapid onset and offset of action because of its low blood-gas partition co-efficient 8 . This may be a useful property when this agent is used for therapeutic uterine relaxation. Rapid washin may allow the obstetric anaesthetist to provide more rapid uterine relaxation, which could be advantageous in the emergency setting. Rapid washout of sevoflurane may result in a more rapid increase in uterine tone when uterine relaxation is no longer required, although after high concentrations, washout is not likely to be as rapid. Maternal considerations aside, rapid washout may also benefit the neonate following delivery. These considerations remain speculative, are based on drug pharmacology and have not yet been investigated clinically. Sevoflurane produces less cardiovascular depression than isoflurane 9 . Maternal cardiovascular depression has been associated with placental hypoperfusion and fetal compromise. Placental hypoperfusion is a particular risk during the EXIT procedure, where high concentrations of the volatile agents are required. The principal disadvantage to the use of sevoflurane for uterine relaxation has been the lack of available information about its effect on uterine muscle tone.
From 0.1-3.5 MAC, sevoflurane produces dosedependent depression of contractility with an ED 50 of 0.94 MAC. This suggests that sevoflurane can cause significant uterine muscle relaxation, leading us to conclude that it may be effective in the clinical setting for therapeutic uterine relaxation. Sevoflurane depresses both the amplitude and the duration of an individual contraction, so contractility (area under the force-time curve), which incorporates both these measurements, is more depressed than developed tension for equivalent concentration of drug. We propose that contractility is a better measure of uterine activity than developed tension, because the latter does not take into account the temporal component of the contraction.
The mechanism by which the volatile anaesthetic agents depress uterine muscle contractility is not fully understood. In animal studies on pregnant myometrium, sevoflurane has been found to modulate the activity of the calcium-activated potassium channels, and this may account, at least in part, for the inhibition of myometrial smooth muscle by sevoflurane 31 . It has also been postulated that the volatile agents may influence calcium influx into the smooth muscle cells or reduce the numbers of gap junctions, however neither of these proposed mechanisms has been conclusively demonstrated 32, 33 . The mechanism by which sevoflurane increases the frequency of uterine muscle contraction is unknown. Pacemaker potentials have not been identified in the uterus, although they almost certainly exist, and thus it is difficult to postulate how such an increase might occur.
In conclusion, this study has demonstrated that sevoflurane produces a dose-dependent depression of uterine muscle contractility. Whilst clinical studies are required, we propose that this drug may prove useful for therapeutic uterine muscle relaxation, particularly in situations such as the EXIT procedure, where high concentrations of volatile agents are required to produce uterine quiescence.
